With a one year PEG ratio of 811.36, Inovalon Holdings Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 95.32% of US stocks.
With a price/earnings ratio of 343.33, Inovalon Holdings Inc P/E ratio is greater than that of about 97.9% of stocks in our set with positive earnings.
Price to trailing twelve month operating cash flow for INOV is currently 30.38, higher than 86.81% of US stocks with positive operating cash flow.
If you're looking for stocks that are quantitatively similar to Inovalon Holdings Inc, a group of peers worth examining would be CE, CUB, CCMP, CLGX, and CAMP.
INOV's SEC filings can be seen here. And to visit Inovalon Holdings Inc's official web site, go to www.inovalon.com.
Inovalon Holdings provides advanced cloud-based data analytics and data-driven intervention platforms to the healthcare industry in the United States. The company was founded in 1998 and is based in Bowie, Maryland.
INOV Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for INOV, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Inovalon Holdings Inc ranked in the 13th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. The most interesting components of our discounted cash flow analysis for Inovalon Holdings Inc ended up being:
In the past 5.33 years, Inovalon Holdings Inc has a compound free cash flow growth rate of -0.01%; that's higher than merely 21.08% of free cash flow generating stocks in the Technology sector.
Inovalon Holdings Inc's weighted average cost of capital (WACC) is 9%; for context, that number is higher than 67.15% of tickers in our DCF set.
Inovalon Holdings Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than just 0% of US stocks with positive free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Technology that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as INOV, try FEYE, HPE, SIMO, SPOT, and GRUB.
Second Quarter 2020 Highlights * Q2 revenue of $162.2 million, up 3% YoY * Q2 subscription-based platform revenue of $142.1 million, up 13% YoY, equating to 88% of Q2 total revenue * Q2 net income of $2.0 million, resulting in diluted net income of $0.01 per share * Q2 Non-GAAP net income of $22.0 million, up 15% YoY, resulting in Non-GAAP net income of $0.15 per share * Q2 Adjusted EBITDA of $56.6 million, up 8% YoY, resulting in Adjusted EBITDA margin of 34.9% * Q2 net cash provided by operating activities of $49.0 million * Q2 new sales Annual Contract Value (ACV)1 totaled a record $75.7 million, up 38.1% YoYDebt & Cash Highlights * Voluntarily repaid $99 million (100% of all outstanding amounts) of revolver on June 4, 2020 * Cash balance as of June 30, 2020 totaling $95.6...
Retailer’s Specialty Pharmacy Business to Implement ScriptMed® Cloud Solution to Empower Enhanced Outcomes and Economics for its CustomersBOWIE, Md., July 23, 2020 (GLOBE NEWSWIRE) -- Inovalon (Nasdaq: INOV), a leading provider of cloud-based platforms empowering data-driven healthcare, today announced a long-term engagement with Walmart’s Specialty Pharmacy business (NYSE: WMT) to provide cloud-based capabilities through the Inovalon ONE® Platform as part of its data-driven strategy to improve outcomes and economics for its customers. The high-complexity and high-cost nature of specialty pharmacy stands to benefit significantly from the capabilities enabled through the Inovalon ONE® Platform. Through the implementation of ScriptMed® Cloud, a software-as-a-service (SaaS) cloud offering...